A. Follow previously established guidelines without additional changes B. Avoid prophylactic G-CSF use with intermediate-risk chemotherapy regimens that pose a 10% chance of developing febrile neutropenia C. Use G-CSF prophylactically with intermediate- and high-risk chemotherapy regimens that pose a 10% to 20% chance of developing febrile neutropenia D. Offer G-CSF only to patients that have previously experienced febrile neutropenia to keep patients on chemotherapy out of the clinic E. Unsure

A. Biosimilars must undergo the same testing as a novel drug B. Biosimilars must undergo vigorous additional testing in the intent-to-treat population (i.e., patients with cancer) to demonstrate superiority to the originator product C. Biosimilars must only demonstrate efficacy, safety, and adequate biologic activity with pharmacokinetic and pharmacodynamic studies compared to the originator product D. Biosimilars must undergo analytical, animal, immunogenicity, pharmacokinetic, and pharmacodynamic studies comparing it to the originator product E. Unsure

A. Economic value B. Product storage C. Immunogenicity D. Efficacy data E. Unsure

A. Provider acceptance B. Payer formulary C. Product nomenclature D. Product administration E. Unsure

A. Information technology support for electronic medical record B. Create biosimilar task force with only pharmacists and physicians C. Educational strategies for key stakeholders (e.g., health care staff and patients) D. Transition plan for biosimilar implementation and initiation E. Unsure